{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:54:51Z","timestamp":1794005691435,"version":"4.8.0"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["93-01-49-8878"],"award-info":[{"award-number":["93-01-49-8878"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2020,1,7]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Inflammation, oxidative stress, and adipogenesis are associated with Graves\u2019 ophthalmopathy (GO) progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>We conducted a pilot study to investigate the effect of Enalapril on patients with mild ophthalmopathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p>Based on the comprehensive eye examination, 12 patients with mild ophthalmopathy were selected from referred Graves\u2019 patients and treated with Enalapril (5 mg daily) for 6 months. Clinical and ophthalmological examination [IOP (Intraocular Pressure), vision, Margin reflex distance and exophthalmia measurement, CAS (clinical activity score) and VISA [V (vision); I (inflammation\/ congestion); S (strabismus\/motility restriction); and A (appearance\/exposure] score assessment) was performed at the beginning, 3 months and 6 months of the study period. Quality of life was also evaluated using a standard questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Mean exophthalmia at the first visit was 18.75 \u00b1 2.39, 3 months later 18.53 \u00b1 2.39 and 6 months later was 17.92 \u00b1 2.31, respectively. Mean CAS was 0.71 \u00b1 0.82 (first visit), 0.57 \u00b1 0.54 (3 months) and 0.14 \u00b1 0.36 (6 months), respectively. Mean Margin reflex distance was 9.09 \u00b1 4.36 (first visit) and 9.60 \u00b1 4.40 (6 months), respectively. There were significant differences in the case of exophthalmia (P=0.002), CAS (P=0.006), and Margin reflex distance (P=0.029) between the first visit and 6 months after treatment. The difference between the score of quality of life in patients with GO after 6 months of follow up was statistically significant (P = 0.006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Our results showed that Enalapril treatment could ameliorate the clinical course of GO according to the ophthalmologic examinations and subjective parameters of disease progression. However, further studies should be performed to determine the efficacy of Enalapril in Graves\u2019 ophthalmopathy treatment.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389201020666190725113816","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T18:47:00Z","timestamp":1578422820000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves\u2019 Ophthalmopathy: A Pilot Study"],"prefix":"10.2174","volume":"20","author":[{"given":"Ghazal","family":"Ataabadi","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-0376","authenticated-orcid":true,"given":"Mohammad H.","family":"Dabbaghmanesh","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Endocrinology and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Owji","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-6311","authenticated-orcid":true,"given":"Marzieh","family":"Bakhshayeshkaram","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-1415","authenticated-orcid":true,"given":"Nima","family":"Montazeri-Najafabady","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Endocrinology and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.autrev.2014.01.013","volume":"13","author":"Menconi F.","year":"2014","unstructured":"Menconi F.; Marcocci C.; Marin\u00f2 M.; Diagnosis and classification of Graves\u2019 disease. Autoimmun Rev 2014,13(4-5),398-402","journal-title":"Autoimmun Rev"},{"key":"ref=2","first-page":"693","volume":"47","author":"Rostamzadeh D.","year":"2015","unstructured":"Rostamzadeh D.; Dabbaghmanesh M.H.; Shabani M.; Hosseini A.; Amirghofran Z.; Expression Profile of Human Fc Receptor- Like 1, 2, and 4 Molecules in Peripheral Blood Mononuclear Cells of Patients with Hashimoto's Thyroiditis and Graves' Disease, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2015,47(9),693-8"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"De Leo S.","year":"2016","unstructured":"De Leo S.; Lee S.Y.; Braverman L.E.; Hyperthyroidism. Lancet 2016,388(10047),906-918","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12020-008-9107-5","volume":"34","author":"Kaykhaei M.A.","year":"2008","unstructured":"Kaykhaei M.A.; Shams M.; Sadegholvad A.; Dabbaghmanesh M.H.; Omrani G.R.; Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine 2008,34(1-3),52-55","journal-title":"Endocrine"},{"key":"ref=5","first-page":"150","volume":"10","author":"Ashouri E.","year":"2013","unstructured":"Ashouri E.; Dabbaghmanesh M.H.; Hadaegh A.; Rowhanirad S.; Bakhshayashkaram M.; Omrani G.R.; KIR gene content does not contribute to susceptibility to Graves\u2019 disease. Iran J Immunol 2013,10(3),150-157","journal-title":"Iran J Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4149\/endo_2011_04_209","volume":"45","author":"Karoutsou E.","year":"2011","unstructured":"Karoutsou E.; Polymeris A.; Pathogenesis of Graves\u2019 disease focusing on Graves\u2019 ophthalmopathy. Endocr Regul 2011,45(4),209-220","journal-title":"Endocr Regul"},{"key":"ref=7","first-page":"841","volume":"14","author":"Razavi M.E.","year":"2008","unstructured":"Razavi M.E.; Abotoraby R.B.; Kakhki R.D.; Ghanavati S.Z.; Layegh P.; Taghavi M.; Rajabian M.T.; Clinical evaluation of Graves ophthalmopathy in north-east Islamic Republic of Iran, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq almutawassit 2008,14(4),841-9"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2265.1995.tb02681.x","volume":"42","author":"Paschke R.","year":"1995","unstructured":"Paschke R.; Vassart G.; Ludgate M.; Current evidence for and against the TSH receptor being the common antigen in Graves\u2019 disease and thyroid associated ophthalmopathy. Clin Endocrinol 1995,42(6),565-569","journal-title":"Clin Endocrinol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1055\/s-0035-1555956","volume":"47","author":"Banga J.P.","year":"2015","unstructured":"Banga J.P.; Moshkelgosha S.; Berchner-Pfannschmidt U.; Eckstein A.; Modeling Graves\u2019 orbitopathy in experimental Graves\u2019 disease. Horm Metab Res 2015,47(10),797-803","journal-title":"Horm Metab Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s40618-016-0484-y","volume":"39","author":"Li H.X.","year":"2016","unstructured":"Li H.X.; Xiang N.; Hu W.K.; Jiao X.L.; Relation between therapy options for Graves\u2019 disease and the course of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest 2016,39(11),1225-1233","journal-title":"J Endocrinol Invest"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1507\/endocrj.50.429","volume":"50","author":"Akamizu T.","year":"2003","unstructured":"Akamizu T.; Nakamura Y.; Tamaoki A.; Inaba Y.; Amino N.; Seino Y.; Prevalence and clinico-epidemiology of familial Graves\u2019 disease in Japan based on nationwide epidemiologic survey in 2001. Endocr J 2003,50(4),429-436","journal-title":"Endocr J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"J307","DOI":"10.1016\/j.jaut.2009.11.019","volume":"34","author":"Hemminki K.","year":"2010","unstructured":"Hemminki K.; Li X.; Sundquist J.; Sundquist K.; The epidemiology of Graves\u2019 disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010,34(3),J307-J313","journal-title":"J Autoimmun"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"Prabhakar B.S.","year":"2003","unstructured":"Prabhakar B.S.; Bahn R.S.; Smith T.J.; Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr Rev 2003,24(6),802-835","journal-title":"Endocr Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1016\/j.peptides.2006.04.015","volume":"27","author":"Carneiro-Ramos M.S.","year":"2006","unstructured":"Carneiro-Ramos M.S.; Silva V.B.; Santos R.A.; Barreto-Chaves M.L.; Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism. Peptides 2006,27(11),2942-2949","journal-title":"Peptides"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.mehy.2007.09.014","volume":"70","author":"Sagheb M.M.","year":"2008","unstructured":"Sagheb M.M.; Owji N.; Moini M.; Potential benefit of angiotensin converting enzyme inhibitors for hindering progression of Graves\u2019 ophthalmopathy. Med Hypotheses 2008,70(4),895","journal-title":"Med Hypotheses"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3904\/kjim.1986.1.1.104","volume":"1","author":"Lee D.S.","year":"1986","unstructured":"Lee D.S.; Chung J.K.; Cho B.Y.; Koh C.S.; Lee M.; Changes of serum angiotensin-converting enzyme activity during treatment of patients with Graves\u2019 disease. Korean J Intern Med 1986,1(1),104-112","journal-title":"Korean J Intern Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2165\/00003088-199325040-00003","volume":"25","author":"MacFadyen R.J.","year":"1993","unstructured":"MacFadyen R.J.; Meredith P.A.; Elliott H.L.; Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. Clin Pharmacokinet 1993,25(4),274-282","journal-title":"Clin Pharmacokinet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/nep.12134","volume":"18","author":"He Y.M.","year":"2013","unstructured":"He Y.M.; Feng L.; Huo D.M.; Yang Z.H.; Liao Y.H.; Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton) 2013,18(9),605-614","journal-title":"Nephrology (Carlton)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1753944716644130","volume":"10","author":"D\u00fcsing R.","year":"2016","unstructured":"D\u00fcsing R.; Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Ther Adv Cardiovasc Dis 2016,10(3),151-161","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.mcna.2012.01.014","volume":"96","author":"Stan M.N.","year":"2012","unstructured":"Stan M.N.; Garrity J.A.; Bahn R.S.; The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 2012,96(2),311-328","journal-title":"Med Clin North Am"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/249125","author":"Barrio-Barrio J.","year":"2015","unstructured":"Barrio-Barrio J.; Sabater A.L.; Bonet-Farriol E.; Vel\u00e1zquez-Villoria \u00c1.; Galofr\u00e9 J.C.; Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol 2015","journal-title":"J Ophthalmol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jfo.2016.09.009","volume":"39","author":"Achiron A.","year":"2016","unstructured":"Achiron A.; Blumenfeld O.; Avizemer H.; Karmona L.; Leybowich G.; Man V.; Bartov E.; Burgansky-Eliash Z.; Intraocular pressure measurement after DSAEK by iCare, Goldmann applanation and dynamic contour tonometry: A comparative study. J Fr Ophtalmol 2016,39(10),822-828","journal-title":"J Fr Ophtalmol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/01676830490504089","volume":"23","author":"Mourits M.P.","year":"2004","unstructured":"Mourits M.P.; Lombardo S.H.; van der Sluijs F.A.; Fenton S.; Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves\u2019 patients. An exploratory study. Orbit 2004,23(3),161-168","journal-title":"Orbit"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/0002-9394(69)91246-X","volume":"68","author":"Werner S.C.","year":"1969","unstructured":"Werner S.C.; Classification of the eye changes of Graves\u2019 disease. Am J Ophthalmol 1969,68(4),646-648","journal-title":"Am J Ophthalmol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0002-9394(77)90140-4","volume":"83","author":"Werner S.C.","year":"1977","unstructured":"Werner S.C.; Modification of the classification of the eye changes of Graves\u2019 disease. Am J Ophthalmol 1977,83(5),725-727","journal-title":"Am J Ophthalmol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0895-4356(99)00069-4","volume":"52","author":"Terwee C.B.","year":"1999","unstructured":"Terwee C.B.; Gerding M.N.; Dekker F.W.; Prummel M.F.; van der Pol J.P.; Wiersinga W.M.; Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy. J Clin Epidemiol 1999,52(9),875-884","journal-title":"J Clin Epidemiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"Terwee C.B.","year":"1998","unstructured":"Terwee C.B.; Gerding M.N.; Dekker F.W.; Prummel M.F.; Wiersinga W.M.; Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998,82(7),773-779","journal-title":"Br J Ophthalmol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","volume":"53","author":"Hiromatsu Y.","year":"2014","unstructured":"Hiromatsu Y.; Eguchi H.; Tani J.; Kasaoka M.; Teshima Y.; Graves\u2019 ophthalmopathy: epidemiology and natural history. Intern Med 2014,53(5),353-360","journal-title":"Intern Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrendo.2014.226","volume":"11","author":"Smith T.J.","year":"2015","unstructured":"Smith T.J.; TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol 2015,11(3),171-181","journal-title":"Nat Rev Endocrinol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","volume":"99","author":"Chen H.","year":"2014","unstructured":"Chen H.; Mester T.; Raychaudhuri N.; Kauh C.Y.; Gupta S.; Smith T.J.; Douglas R.S.; Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 2014,99(9),E1635-E1640","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"Tsui S.","year":"2008","unstructured":"Tsui S.; Naik V.; Hoa N.; Hwang C.J.; Afifiyan N.F.; Sinha Hikim A.; Gianoukakis A.G.; Douglas R.S.; Smith T.J.; Evidence for an association between thyroid-stimulating hormone and insulin- like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease, Journal of immunology (Baltimore, Md : 1950) 2008,181(6),4397-405","journal-title":"Journal of immunology (Baltimore, Md : 1950)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MNM.0b013e32834121cb","volume":"32","author":"Yan S.X.","year":"2011","unstructured":"Yan S.X.; Wang Y.; Peng G.J.; Lu X.P.; Fu Y.; Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves\u2019 ophthalmopathy. Nucl Med Commun 2011,32(2),142-146","journal-title":"Nucl Med Commun"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/thy.2012.0373","volume":"23","author":"Botta R.","year":"2013","unstructured":"Botta R.; Lisi S.; Marcocci C.; Sellari-Franceschini S.; Rocchi R.; Latrofa F.; Menconi F.; Altea M.A.; Leo M.; Sisti E.; Casini G.; Nardi M.; Pinchera A.; Vitti P.; Marin\u00f2 M.; Enalapril Reduces Proliferation and Hyaluronic Acid Release in Orbital Fibroblasts, Thyroid : official journal of the American Thyroid Association 2013,23(1),92-96","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"Bahn R.S.","year":"2010","unstructured":"Bahn R.S.; Graves\u2019 ophthalmopathy. N Engl J Med 2010,362(8),726-738","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"28049","DOI":"10.1016\/S0021-9258(18)46893-7","volume":"269","author":"Gilbert M.T.","year":"1994","unstructured":"Gilbert M.T.; Sun J.; Yan Y.; Oddoux C.; Lazarus A.; Tansey W.P.; Lavin T.N.; Catanzaro D.F.; Renin gene promoter activity in GC cells is regulated by cAMP and thyroid hormone through Pit-1-dependent mechanisms. J Biol Chem 1994,269(45),28049-28054","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.2337\/dc06-0911","volume":"29","author":"Langham R.G.","year":"2006","unstructured":"Langham R.G.; Kelly D.J.; Gow R.M.; Zhang Y.; Cordonnier D.J.; Pinel N.; Zaoui P.; Gilbert R.E.; Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 2006,29(12),2670-2675","journal-title":"Diabetes Care"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2004.08.023","volume":"178","author":"da Cunha V.","year":"2005","unstructured":"da Cunha V.; Tham D.M.; Martin-McNulty B.; Deng G.; Ho J.J.; Wilson D.W.; Rutledge J.C.; Vergona R.; Sullivan M.E.; Wang Y.X.; Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005,178(1),9-17","journal-title":"Atherosclerosis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.bcp.2009.06.018","volume":"78","author":"Santos E.L.","year":"2009","unstructured":"Santos E.L.; de Picoli Souza K.; da Silva E.D.; Batista E.C.; Martins P.J.; D\u2019Almeida V.; Pesquero J.B.; Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem Pharmacol 2009,78(8),951-958","journal-title":"Biochem Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/biof.552029207","volume":"29","author":"Dabbaghmanesh M.H.","year":"2007","unstructured":"Dabbaghmanesh M.H.; Sadegholvaad A.; Ejtehadi F.; Omrani G.; Low serum selenium concentration as a possible factor for persistent goiter in Iranian school children. Biofactors 2007,29(2-3),77-82","journal-title":"Biofactors"},{"key":"ref=40","first-page":"459","volume":"39","author":"Assaei R.","year":"2014","unstructured":"Assaei R.; Zal F.; Mostafavi-Pour Z.; Dabbaghmanesh M.H.; Geramizadeh B.; Ranjbar Omrani G.H.; Pajouhi N.; Hepatoprotective effect of satureja khuzestanica essential oil and vitamin e in experimental hyperthyroid rats: evidence for role of antioxidant effect. Iran J Med Sci 2014,39(5),459-466","journal-title":"Iran J Med Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1167\/iovs.15-16870","volume":"56","author":"Kim C.Y.","year":"2015","unstructured":"Kim C.Y.; Lee H.J.; Chae M.K.; Byun J.W.; Lee E.J.; Yoon J.S.; Therapeutic Effect of Resveratrol on Oxidative Stress in Graves\u2019 Orbitopathy Orbital Fibroblasts. Invest Ophthalmol Vis Sci 2015,56(11),6352-6361","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"R572","DOI":"10.1152\/ajpregu.2000.278.3.R572","volume":"278","author":"de Cavanagh E.M.","year":"2000","unstructured":"de Cavanagh E.M.; Inserra F.; Ferder L.; Fraga C.G.; Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol 2000,278(3),R572-R577","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2249.2010.04191.x","volume":"161","author":"Vannucchi G.","year":"2010","unstructured":"Vannucchi G.; Campi I.; Bonomi M.; Covelli D.; Dazzi D.; Curr\u00f2 N.; Simonetta S.; Bonara P.; Persani L.; Guastella C.; Wall J.; Beck-Peccoz P.; Salvi M.; Rituximab treatment in patients with active Graves\u2019 orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 2010,161(3),436-443","journal-title":"Clin Exp Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"Smith T.J.","year":"2017","unstructured":"Smith T.J.; Kahaly G.J.; Ezra D.G.; Fleming J.C.; Dailey R.A.; Tang R.A.; Harris G.J.; Antonelli A.; Salvi M.; Goldberg R.A.; Gigantelli J.W.; Couch S.M.; Shriver E.M.; Hayek B.R.; Hink E.M.; Woodward R.M.; Gabriel K.; Magni G.; Douglas R.S.; Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 2017,376(18),1748-1761","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1590\/S0004-27492006000600006","volume":"69","author":"Stamato F.J.","year":"2006","unstructured":"Stamato F.J.; Maciel R.M.; Manso P.G.; Wolosker A.M.; Paiva E.R.; Lopes A.C.; Furlanetto R.P.; Colchicine in the treatment of the inflammatory phase of Graves\u2019 ophthalmopathy: a prospective and randomized trial with prednisone. Arq Bras Oftalmol 2006,69(6),811-816","journal-title":"Arq Bras Oftalmol"},{"key":"ref=46","author":"Almeda-Valdes P.","year":"2013","unstructured":"Almeda-Valdes P.; Cuevas-Ramos D.; Gomez-Samano M.A.; Cardenas-Velazquez F.; Perez-Enriquez B.; Abundes-Corona A.; Gomez-Perez F.J.; SUN-435: Favorable effects of bromocriptine and pentoxifylline in the treatment of mild to moderate Graves' disease associated ophthalmopathy. A randomized, controlled, single blind, clinical trial 2013","journal-title":"A randomized, controlled, single blind, clinical trial"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"Marcocci C.","year":"2011","unstructured":"Marcocci C.; Kahaly G.J.; Krassas G.E.; Bartalena L.; Prummel M.; Stahl M.; Altea M.A.; Nardi M.; Pitz S.; Boboridis K.; Sivelli P.; von Arx G.; Mourits M.P.; Baldeschi L.; Bencivelli W.; Wiersinga W.; European Group on Graves\u2019 Orbitopathy. Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 2011,364(20),1920-1931","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1590\/S0004-27302011000900004","volume":"55","author":"Bloise W.","year":"2011","unstructured":"Bloise W.; Mimura L.Y.; Moura J.; Nicolau W.; Treatment of mild to moderate Graves\u2019 ophthalmopathy with sodium diclofenac: a pilot study. Arq Bras Endocrinol Metabol 2011,55(9),692-695","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1210\/er.21.2.168","volume":"21","author":"Bartalena L.","year":"2000","unstructured":"Bartalena L.; Pinchera A.; Marcocci C.; Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 2000,21(2),168-199","journal-title":"Endocr Rev"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T17:29:21Z","timestamp":1613410161000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173864\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201020666190725113816","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}